瘤衍生的细胞外囊泡使瘤热带化疗-基因疗法可用于三阴性乳腺癌的局部免疫激活
Zaihui Peng1, Tingting Zhao1, Pingping Gao1
1Department of Breast and Thyroid Surgery, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China.
ACS nano
|October 30, 2024
概括
这项研究引入了一种新的三阴性乳腺癌 (TNBC) 疗法,该疗法结合了基因,化疗和免疫疗法,使用瘤衍生的细胞外囊泡 (TEV). 这种方法有效地向瘤,减少免疫抑制,并激活抗瘤免疫力.
科学领域:
- 在瘤学瘤学.
- 生物技术是生物技术.
- 免疫治疗是一种免疫疗法.
背景情况:
- 三阴性乳腺癌 (TNBC) 是一种异质性疾病,具有有限的向疗法和免疫抑制性瘤微环境 (TME).
- 目前的治疗方法,如化疗和免疫检查点抑制剂,面临治疗耐药性和TME调节的挑战.
- 迫切需要创新的策略来克服TNBC耐药性并提高治疗疗效.
研究的目的:
- 通过整合基因疗法,化疗和免疫疗法,开发TNBC的协同治疗策略.
- 利用瘤衍生的细胞外囊泡 (TEVs) 来针对性地输送STAT3短干扰RNA (siSTAT3) 和多克索鲁比 (DOX).
- 研究siSTAT3-DOX@TEV在重塑TME和增强抗瘤免疫反应方面的潜力.
主要方法:
- 使用siSTAT3和DOX的TEV功能化,以创建siSTAT3-DOX@TEV纳米粒子.
- 在体外和体内对siSTAT3-DOX@TEV进行瘤向和STAT3通路抑制的评估.
- 使用质细胞计和免疫组织化学评估免疫性细胞死亡诱导和TME调制.
主要成果:
- siSTAT3-DOX@TEV证明了精确的瘤组织向和有效下调STAT3表达.
- 联合疗法协同诱导免疫细胞死亡,导致免疫抑制TME的逆转.
- 在瘤组织内观察到M1巨细胞,CD4+和CD8+T细胞的显著增加,这表明局部免疫激活.
结论:
- 基于TEV的siSTAT3和DOX的输送为TNBC治疗提供了一个有希望的协同方法.
- 这一策略有效地重塑了免疫抑制的TME,并刺激了抗瘤免疫力.
- siSTAT3-DOX@TEV代表了TNBC管理中先进的化疗基因治疗药物的潜在临床候选者.
更多相关视频
08:50Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
Published on: August 16, 2024
642
11:15A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
10.2K
相关概念视频
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
01:27Tumor Immunotherapy
486
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
486
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:30Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K